Merck Lands Cancer Fighter Harpoon Therapeutics For $680M
By Cassie M. Chew · January 8, 2024, 6:14 PM EST
Merck has entered into an agreement to acquire Harpoon Therapeutics, a cancer immunotherapy company founded eight years ago, for $23 per share in cash for an approximate total equity value of...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login